Targeting the Oncoprotein MDMX as a Novel Treatment for Triple Negative Breast Cancer [ 2017 - 2019 ]

Research Grant

Researchers: Prof Ygal Haupt (Principal investigator) ,  A/Pr Elgene Lim

Brief description Breast cancer (BrCa) is a leading cause of cancer death in women worldwide. BrCas unable to respond to current therapies have the worst outcomes. We propose a novel strategy to treat these cancers, based on our new findings. Our two protein targets are: (1) MDMX, that we found drives BrCa with its partner, (2) mutant p53, which causes cancer spread. We plan to directly target these drivers of aggressive BrCas, using new drugs that individually show great promise in trials in a number of cance

Funding Amount $AUD 575,006.29

Funding Scheme Project Grants

Notes Standard Project Grant